Longevity · Thymic

Thymalin

Thymalin is a complex of thymic peptides extracted from calf thymus, studied for immune restoration in elderly and immunocompromised patients. Used clinically in Russia and Eastern Europe.

Category: Longevity Last updated 2026-06-19

Thymalin at a glance

Thymalin is a complex of thymic peptides extracted from calf thymus, studied for immune restoration in elderly and immunocompromised patients. Used clinically in Russia and Eastern Europe. Mechanism: Thymic peptide complex. Typical route: Intramuscular. FDA status: Not FDA-approved. Approved and used in Russia and former Soviet states. Imported by some U.S. compounding and integrative-medicine practices for off-label use.

Drug classThymic peptide complex

Half-lifeVaries (cocktail)

RouteIntramuscular

Common dosing10-30 mg, 5-10 day course

FDA statusNot approved (US)

Russia approvalYes, immune indications

Mechanism of action

Thymalin acts on T-cell maturation and immune balance, restoring age-related decline in thymic function. Russian clinical studies report decreased infections and improvements in markers of immunosenescence in elderly subjects.

Dosing reference

Intramuscular: 10-30 mg per dose, given 5-10 days as a treatment course, then off for 2-6 months. Specific dosing varies by indication.

Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.

FDA status & regulatory framework

Not FDA-approved. Approved and used in Russia and former Soviet states. Imported by some U.S. compounding and integrative-medicine practices for off-label use.

U.S. telehealth providers that work with Thymalin

#1 of 4

Defy Medical

88/100v3.0 six-pillar rubric

Starting at $160/mo. Defy Medical is one of the providers covered in our editorial directory that dispenses or coordinates Thymalin.

Read review →

#2 of 4

Marek Health

85/100v3.0 six-pillar rubric

Starting at $180/mo. Marek Health is one of the providers covered in our editorial directory that dispenses or coordinates Thymalin.

Read review →

#3 of 4

BreezeMeds

68/100v3.0 six-pillar rubric

Starting at $199/mo. BreezeMeds is one of the providers covered in our editorial directory that dispenses or coordinates Thymalin.

Read review →

#4 of 4

Hone Health

80/100v3.0 six-pillar rubric

Starting at $149/mo. Hone Health is one of the providers covered in our editorial directory that dispenses or coordinates Thymalin.

Read review →

Related longevity peptides

Browse the full Longevity category →

Frequently asked questions about Thymalin

Is Thymalin the same as Thymosin Alpha-1?

No. Thymalin is a complex of multiple thymic peptides extracted from calf thymus. Thymosin Alpha-1 is a single defined peptide. The two have overlapping but distinct immune effects.

Where is Thymalin used clinically?

Thymalin has been used in Russian and Eastern European clinical practice for decades, particularly for elderly immune-decline indications. U.S. use is off-label through compounding pharmacies.

Lead Medical Researcher

Dr. Sam Saberian

Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.

Medical Reviewer

Alen A. Schwartz, MD

Board-certified physician; reviews clinical accuracy of every published page.

Edited by

Julliana Edwards

Editorial standards, factual accuracy, and corrections workflow.

Clinical evidence and access data

This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.

Evidence point	Published data	What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1	Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.	Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1	Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.	Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status	FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.	Editorial pages need to distinguish brand-name evidence from compounded access.
State access	Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.	Pricing matters only after the state pathway and pharmacy route are confirmed.

Trial outcome chart

Semaglutide 2.4 mg-14.9%

Tirzepatide 15 mg-20.9%

Semaglutide placebo-2.4%

Tirzepatide placebo-3.1%

Sources

Compare NexLife GLP-1 pricing

Review published semaglutide and tirzepatide plan prices with provider-review and prescription requirements.

Check NexLife pricing